Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference 1
 Statera Biopharma, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, will participate in the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2001Michael K. Handley, President and Chief Executive Officer of Statera, will participate in a virtual fireside chat on Thursday, September 30, 2021.

Details for the fireside chat include:


Cantor Global Healthcare Conference


September 30, 2021


12:40 – 1:10 p.m. ET

A webcast of the discussion will be available on the Investor Relations section of the Statera website following the conference. Investors who wish to register for the conference should contact their Cantor Fitzgerald sales representative.

Formerly known as Cytocom, Inc., Statera emerged as a publicly traded entity following the reverse merger between the former Cleveland BioLabs and the formerly private Cytocom Inc., which was completed on July 27, 2021. The company announced its new corporate name, Statera BioPharma, on August 31, 2021. 

About Statera Biopharma 
Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. To learn more about Statera Biopharma, please visit

See Campaign:
Contact Information:

Wire, Legal Newswire, United States, English